Pathogenesis of Comorbid Epilepsy in Alzheimer's Disease and the Role of Perampanel as an AMPA Receptor Inhibitor

Alzheimer's disease and epilepsy frequently co-occur and share common pathogenic mechanisms involving AMPA-type glutamate receptors. Perampanel, an FDA-approved AMPAR antagonist for seizure management, may offer therapeutic benefits in patients with comorbid AD-epilepsy, particularly those with myoclonus or sleep disturbances, though clinical evidence remains limited.